慢性肾脏病中骨骼、血管、心脏和肾脏的激活素受体被刺激
该研究在75日龄Alport综合征小鼠中启动ActRIIA配体陷阱RAP-011,评估ActRIIA信号激活在CKD中的作用。200日龄时,RAP-011逆转骨吸收和成骨细胞功能障碍、增加骨形成,预防主动脉钙化并降低主动脉钙浓度,改善心脏肥大、GFR和BUN,减轻肾脏炎症和纤维化。结论是早期CKD中ActRIIA信号激活参与CKD-MBD和肾纤维化,抑制该信号可改善和延缓CKD-MBD。
要点
- RAP-011抑制ActRIIA可逆转CKD小鼠骨吸收和成骨细胞功能障碍并增加骨形成。
- RAP-011预防主动脉钙化,降低主动脉钙浓度并改善心脏肥大。
- RAP-011改善GFR和BUN,减轻肾脏炎症和间质纤维化。
核心结论
- 早期CKD中ActRIIA信号激活参与CKD-MBD的骨营养不良和心血管疾病以及肾纤维化。
- 抑制ActRIIA信号在该Alport综合征模型中有效改善和延缓CKD-MBD。
研究设计与样本
- 使用75日龄Alport综合征小鼠,以ActRIIA配体陷阱RAP-011进行干预。
- 在200日龄时评估严重CKD及CKD-MBD相关指标。
主要发现
- RAP-011逆转CKD诱导的骨吸收和成骨细胞功能障碍,并增加骨形成。
- RAP-011预防主动脉外膜和中膜钙磷灰石沉积,将平均主动脉钙浓度从0.59降至0.36 mg/g。
- 未治疗小鼠心脏重量显著增加26%,RAP-011治疗组保持正常。
- 150日龄时,未治疗组GFR显著降低55%,RAP-011组仅降低30%。
- 200日龄时,未治疗组平均BUN为100 mg/dl,治疗组为60 mg/dl。
关键数值与推荐
- 平均主动脉钙浓度:未治疗组0.59 mg/g,RAP-011治疗组0.36 mg/g。
- 心脏重量:未治疗组显著增加26%,RAP-011治疗组正常。
- 150日龄GFR:未治疗组显著降低55%,RAP-011组降低30%。
- 200日龄平均BUN:未治疗组100 mg/dl,RAP-011组60 mg/dl。
临床怎么用
- ActRIIA信号通路可能是CKD-MBD和肾纤维化的潜在治疗靶点。
- RAP-011在Alport综合征小鼠模型中显示改善骨病、血管钙化、心脏肥大和肾功能的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We examined activin receptor type IIA (ActRIIA) activation in chronic kidney disease (CKD) by signal analysis and inhibition in mice with Alport syndrome using the ActRIIA ligand trap RAP-011 initiated in 75-day-old Alport mice. At 200 days of age, there was severe CKD and associated Mineral and Bone Disorder (CKD-MBD), consisting of osteodystrophy, vascular calcification, cardiac hypertrophy, hyperphosphatemia, hyperparathyroidism, elevated FGF23, and reduced klotho. The CKD-induced bone resorption and osteoblast dysfunction was reversed, and bone formation was increased by RAP-011. ActRIIA inhibition prevented the formation of calcium apatite deposits in the aortic adventitia and tunica media and significantly decreased the mean aortic calcium concentration from 0.59 in untreated to 0.36 mg/g in treated Alport mice. Aortic ActRIIA stimulation in untreated mice increased p-Smad2 levels and the transcription of sm22α and αSMA. ActRIIA inhibition reversed aortic expression of the osteoblast transition markers Runx2 and osterix. Heart weight was significantly increased by 26% in untreated mice but remained normal during RAP-011 treatment. In 150-day-old mice, GFR was significantly reduced by 55%, but only by 30% in the RAP-011-treated group. In 200-day-old mice, the mean BUN was 100 mg/dl in untreated mice compared to 60 mg/dl in the treated group. In the kidneys of 200-day-old mice, ActRIIA and p-Smad2 were induced and MCP-1, fibronectin, and interstitial fibrosis were stimulated; all were attenuated by RAP-011 treatment. Hence, the activation of ActRIIA signaling during early CKD contributes to the CKD-MBD components of osteodystrophy and cardiovascular disease and to renal fibrosis. Thus, the inhibition of ActRIIA signaling is efficacious in improving and delaying CKD-MBD in this model of Alport syndrome.
引用
- Williams MJ, Sugatani T, Agapova OA, et al. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease. Kidney Int. 2017. PMID: 28843411. doi:10.1016/j.kint.2017.06.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。